Clinical Breakthrough: Palatin Technologies Unveils Positive Phase 3 Results for PL9643 in Dry Eye Disease Treatment, Paving the Way for FDA Approval Talks
Palatin Technologies, Inc. announced positive Phase 3 trial results for PL9643, a potential treatment for dry eye disease (DED), presented by Dr. Eric Donnenfeld at the American Society of Cataract and Refractive Surgery Conference.
The study showed statistically significant improvement in pain and multiple secondary symptoms and signs of DED over a 12-week treatment period, with rapid onset of efficacy observed at 2 weeks. PL9643 demonstrated excellent safety and tolerability compared to existing treatments, with fewer adverse events and study discontinuations.
Discussions with the FDA for regulatory approval are planned for the second quarter of 2024. This news indicates a positive development in the treatment of DED and suggests potential future market opportunities for PL9643.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
研究生 : Will it start at 3 yuan